Yizhen Liu

Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B‐Cell Lymphoma: A Retrospective Study

Zhenbo Hou, Kebing Chen, Yuling Lu, Xuejun Ma et autres

BACKGROUND: Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma with heterogeneous clinical features and survival outcomes. Although most patients respond favorably to modern immunochemotherapy, reliable baseline prognostic indicators remain insufficiently defined. METHODS: We retrospectively analyzed 424 patients with …

cn (code pays fourni par la source)

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study

Qunling Zhang, Shiyu Jiang, Ran Wei, Wenhao Zhang et autres

Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are associated with aberrant BCR signaling, and prior …

cn (code pays fourni par la source)

HERVH-derived eRNA activates a super-enhancer–driven ALDH1A3/SAT1 axis to promote ferroptosis escape and pancreatic cancer development

Xiaoli Xu, Yiwen Huang, Dianhui Wei, Zhenbo Hou et autres

Endogenous retroviruses (ERVs), widely distributed in the human genome, are usually epigenetically silenced but can be reactivated in cancer. Activated ERVs may act as regulatory elements or produce noncoding RNAs that modulate gene expression and affect tumor biology. Their role in pancreatic …

cn (code pays fourni par la source)

Prognostic Significance of Deubiquitinase OTUD7B in NK/T‐Cell Lymphoma

Yizhen Liu, Shujuan Wen, Zuguang Xia, Shiyu Jiang et autres

AIM: OTUD7B (ovarian tumor domain-containing 7B) is a deubiquitinase that has established prognostic significance in diffuse large B-cell lymphoma and various solid tumors. In our present work, we aimed to explore its role in NK/T cell lymphoma (NKTCL). METHODS: Expression level of …

cn (code pays fourni par la source)

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial

Yizhen Liu, Qunling Zhang, Fangfang Lv, Xiaojian Liu et autres

Diffuse large B-cell lymphoma (DLBCL) stands as the predominant subtype of non-Hodgkin’s lymphoma (NHL) among adults, accounting for 30–40% of cases globally. Apart from its marked invasiveness, DLBCL demonstrates significant heterogeneity across various parameters, including cellular origin, morphological characteristics, immunohistochemical phenotype, cellular …

cn (code pays fourni par la source)

Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Yizhen Liu, Lingyu Liu, Chuanxu Liu, Wenhao Zhang et autres

Background: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is the most common extranodal marginal zone lymphoma. It could occur at any age, but was often seen in older patients, and most of whom were in low-grade with slow disease progression. There have been …

cn (code pays fourni par la source)

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Guangliang Chen, Jia Jin, Hui Sun, Yizhen Liu et autres

Abstract Background: Primary Central Nervous System Lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma variant confined to the central nervous system. Current treatment primarily uses high-dose methotrexate (MTX) with rituximab, but incomplete responses and relapse are common. Chidamide, an oral histone deacetylase (HDAC) …

cn (code pays fourni par la source)

Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer

Dianhui Wei, Lili Yuan, Xiaoli Xu, Chengsi Wu et autres

cn (code pays fourni par la source)

Chidamide plus R‐ GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Guangliang Chen, Kai Xue, Qunling Zhang, Zuguang Xia et autres

BACKGROUND: In relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targeted therapy for R/R DLBCL by targeting abnormal epigenetic changes associated with poor …

cn (code pays fourni par la source)

Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma

Tiantian Jing, Dianhui Wei, Xiaoli Xu, Chengsi Wu et autres

Transposable elements (TEs) contribute to gene expression regulation by acting as cis-regulatory elements that attract transcription factors and epigenetic regulators. This research aims to explore the functional and clinical implications of transposable element-related molecular events in hepatocellular carcinoma, focusing on the mechanism …

cn (code pays fourni par la source)

Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results

Zuguang Xia, Fangfang Lv, Qunling Zhang, Yizhen Liu et autres

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL). METHODS: …

cn (code pays fourni par la source)

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Guangliang Chen, Kai Xue, Qunling Zhang, Jia Jin et autres

Background: A significant subset of Diffuse large B-cell lymphoma (DLBCL) patients (30%-40%) face treatment failure, necessitating effective salvage chemotherapy. We conducted a phase II study evaluating the efficacy and safety of chidamide plus R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin) in relapsed/refractory (r/r) DLBCL …

cn (code pays fourni par la source)